ID

22302

Description

Study ID: 100151 Clinical Study ID: EGF100151 Study Title: A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Clinicaltrials.gov Identifier: NCT00078572 https://clinicaltrials.gov/ct2/show/NCT00078572 Procedure: Subject Status / Response Assessment, 6 Month Post-Therapy Follow-up Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Breast Cancer; Neoplasms, Breast

Link

https://clinicaltrials.gov/ct2/show/NCT00078572

Keywords

  1. 5/29/17 5/29/17 -
Uploaded on

May 29, 2017

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

XELODA and Lapatinib Advanced or Metastatic Breast Cancer 6 Month Post-Therapy Follow-up NCT00078572

XELODA and Lapatinib Advanced or Metastatic Breast Cancer 6 Month Post-Therapy Follow-up NCT00078572

Subject Status
Description

Subject Status

Alias
UMLS CUI-1
C2348568
UMLS CUI-2
C1522577
UMLS CUI-3
C0678222
Date of assessment
Description

Date of assessment

Data type

date

Alias
UMLS CUI [1]
C0011008
Is the subject alive?
Description

If NO, complete the END OF STUDY RECORD.

Data type

text

Alias
UMLS CUI [1,1]
C2584946
UMLS CUI [1,2]
C2348568
Has this subject started any anti-cancer therapy since the last contact?
Description

anti-cancer therapy

Data type

text

Alias
UMLS CUI [1]
C0920425
If YES, start date of anti-cancer therapy
Description

start date of anti-cancer therapy

Data type

date

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C0920425
Therapy given
Description

Therapy given

Data type

text

Alias
UMLS CUI [1]
C0920425
Response Assessment
Description

Response Assessment

Alias
UMLS CUI-1
C0521982
UMLS CUI-2
C0220825
UMLS CUI-3
C0678222
Has disease progression previously been reported?
Description

If NO, complete the rest of this page.

Data type

text

Alias
UMLS CUI [1]
C0242656
Date of lesion evaluation
Description

lesion

Data type

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C0221198
UMLS CUI [1,3]
C0220825
Response assessment, check one:
Description

Response assessment

Data type

text

Alias
UMLS CUI [1]
C0521982
If progressive disease is checked, indicate the primary method of evaluation.
Description

method

Data type

text

Alias
UMLS CUI [1,1]
C0871511
UMLS CUI [1,2]
C0221198
UMLS CUI [1,3]
C0220825
Date of symptomatic progression of cancer
Description

If Symptomatic progression of cancer is checked, complete details below

Data type

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C0178874
Specify symptoms
Description

Specify symptoms

Data type

text

Alias
UMLS CUI [1,1]
C1457887
UMLS CUI [1,2]
C0178874

Similar models

XELODA and Lapatinib Advanced or Metastatic Breast Cancer 6 Month Post-Therapy Follow-up NCT00078572

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Subject Status
C2348568 (UMLS CUI-1)
C1522577 (UMLS CUI-2)
C0678222 (UMLS CUI-3)
Date of assessment
Item
Date of assessment
date
C0011008 (UMLS CUI [1])
Item
Is the subject alive?
text
C2584946 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
Code List
Is the subject alive?
CL Item
Yes (Y)
CL Item
No (N)
Item
Has this subject started any anti-cancer therapy since the last contact?
text
C0920425 (UMLS CUI [1])
Code List
Has this subject started any anti-cancer therapy since the last contact?
CL Item
Yes (Y)
CL Item
No (N)
start date of anti-cancer therapy
Item
If YES, start date of anti-cancer therapy
date
C0808070 (UMLS CUI [1,1])
C0920425 (UMLS CUI [1,2])
Therapy given
Item
Therapy given
text
C0920425 (UMLS CUI [1])
Item Group
Response Assessment
C0521982 (UMLS CUI-1)
C0220825 (UMLS CUI-2)
C0678222 (UMLS CUI-3)
Item
Has disease progression previously been reported?
text
C0242656 (UMLS CUI [1])
Code List
Has disease progression previously been reported?
CL Item
Yes (Y)
CL Item
No (N)
lesion
Item
Date of lesion evaluation
date
C0011008 (UMLS CUI [1,1])
C0221198 (UMLS CUI [1,2])
C0220825 (UMLS CUI [1,3])
Item
Response assessment, check one:
text
C0521982 (UMLS CUI [1])
Code List
Response assessment, check one:
CL Item
Complete response (CR)
CL Item
Partial response (PR)
CL Item
Stable disease (SD)
CL Item
Progressive disease (PD)
CL Item
Unknown (U)
Item
If progressive disease is checked, indicate the primary method of evaluation.
text
C0871511 (UMLS CUI [1,1])
C0221198 (UMLS CUI [1,2])
C0220825 (UMLS CUI [1,3])
Code List
If progressive disease is checked, indicate the primary method of evaluation.
CL Item
Progressive disease by lesion evaluation (PLE)
CL Item
Symptomatic progression of cancer (SPC)
Date of symptomatic progression of cancer
Item
Date of symptomatic progression of cancer
date
C0011008 (UMLS CUI [1,1])
C0178874 (UMLS CUI [1,2])
Specify symptoms
Item
Specify symptoms
text
C1457887 (UMLS CUI [1,1])
C0178874 (UMLS CUI [1,2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial